Applicability, effect and toleration of dibekacin (Orbicin) were tested in pharmacokinetic, clinical and bacteriological studies treating 29 patients with severe surgical illnesses and 10 healthy volunteers as control group. The pharmacokinetic test results and the efficacy with severe infections showed dibekacin to be equivalent to the new aminoglycoside antibiotics gentamycin, sisomicin and tobramycin. Resistance was sporadic and severe side effects did not occur. Dibekacin proved itself to be a new alternative when aminoglycoside antibiotics are indicated